Marrow cell therapies for cardiovascular diseases.
The nascent field of regenerative medicine has taken root in cardiovascular disease. Preclinical data demonstrating hemangioblast potential of marrow cells and cardioprotective effects of growth factors served as the basis for numerous early phase clinical trials. With the first wave of safety and efficacy trials complete, much is still unknown regarding optimal cell dose and type, timing of injection, route of administration, mechanisms of action, and achievable response measures. The next generation of studies will aim to answers these questions and make way for cellular therapies that result in effective cardiac repair.
Cogle
Christopher R
CR
Department of Medicine, Division of Hematology/Oncology, Program in Stem Cell Biology and Regenerative Medicine, University of Florida College of Medicine, Gainesville, FL 32610-0278, USA. c@ufl.edu
Madlambayan
Gerard J
GJ
Hubsher
Grant
G
Beckman
Chris
C
Speisman
Rachel
R
Tran-Son-Tay
Roger
R
Pepine
Carl J
CJ
D000818:Animals; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation / Q000379:methods*; D002318:Cardiovascular Diseases / Q000601:surgery*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D004195:Disease Models, Animal; D006801:Humans; D017202:Myocardial Ischemia / Q000601:surgery; D016032:Randomized Controlled Trials as Topic